Under the agreement, Rhythm has agreed to repay $6.3 million in cash to RareStone. Rhythm also agreed to return all shares of RareStone that were acquired under the original agreement for no ...

Background and aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) increases circulating LDL levels and cardiovascular disease (CVD) risk; its levels may be related to the dysregulation of ...

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...

Charles Schwab Investment Management Inc. grew its holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Free Report) by ...

The table is a review of notable updates that occurred in February 2025 for investigational products in development.

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66 ...

Incorporating systems thinking into drug value assessment promises more realistic evaluations of the impact of new therapies, ...

Navigation Menu Toggle navigation Sign in Product ...

Click on the status to view our full coverage. Lerodalcibep (LIB Therapeutics) Proprotein convertase subtilisin/kexin type 9 inhibitor To reduce low-density lipoprotein cholesterol in patients ...